Immunosorbents for LDL-apheresis.
Low density lipoprotein (LDL) (1,03-1,05 g/ml) was utilized as antigen to obtain polyclonal (PcAb) and monoclonal (McAb) antibodies. Immunosorbents capable of selective removing LDL from human plasma were developed on the basis of the antibodies preparation. The sorbents called "Immunoliposorber PcAb" and "Immunoliposorber McAb" are currently undergoing clinical trials in the USSR Cardiology Research Center, Acad. of Med. Sciences.
Pokrovsky
S N
SN
Cardiology Research Center, Institute of Experimental Cardiology, Moscow, USSR.
Adamova IYu
Benevolenskaya
G F
GF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007164:Immunosorbents / Q000138:chemical synthesis; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification*; D008422:Materials Testing; D051379:Mice; D008807:Mice, Inbred BALB C; D010956:Plasmapheresis / Q000379:methods; D012756:Sheep
D000911:Antibodies, Monoclonal; D007164:Immunosorbents; D008077:Lipoproteins, LDL